Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties

Bibliography

• Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3:S7-10
   PubMed Web of Science ®Google Scholar
• Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84
   PubMed Web of Science ®Google Scholar
• Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J Clin Psychiatry 2004;65:26-35
   PubMed Web of Science ®Google Scholar
• Drewes AM, Jennum P, Andreasen A, et al. Self-reported sleep disturbances and daytime complaints in women with fibromyalgia and rheumatoid arthritis. J Musculoskeletal Pain 1994;2:15-31
   Google Scholar
• Nicassio PM, Wallston KA. Longitudinal relationships among pain, sleep problems, and depression in rheumatoid arthritis. J Abnorm Psychol 1992;101:514-20
   PubMed Web of Science ®Google Scholar
• Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med 2002;251:207-16
   PubMed Web of Science ®Google Scholar
• Gislason T, Reynisdottir H, Kristbjarnarson H, Benediktsdottir B. Sleep habits and sleep disturbances among the elderly – an epidemiological survey. J Intern Med 1993;234:31-9
   PubMed Web of Science ®Google Scholar
• Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158:1099-107
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006;12:S221-9
   PubMed Web of Science ®Google Scholar
• Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-5
   PubMed Web of Science ®Google Scholar
• James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry 2004;65:752-5
   PubMed Web of Science ®Google Scholar
• Vincent JD, Roche D, Castaing E, et al. Use of human sleep as a test of the psychotropic action of a sample drug: doxepin. Bord Med 1971;4:2651-61
   PubMedGoogle Scholar
• Nowell PD, Reynolds CF 3rd, Buysse DJ, et al. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999;60:89-95
   PubMedGoogle Scholar
• Sakulsripong M, Curran HV, Lader M. Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. Eur J Clin Pharmacol 1991;40:43-8
   PubMed Web of Science ®Google Scholar
• Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther 2006;28:1540-55
   PubMed Web of Science ®Google Scholar
• Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2-8
   PubMed Web of Science ®Google Scholar
• Griebel G, Perrault G, Sanger DJ. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. J Psychopharmacol 1998;12:356-65
   PubMed Web of Science ®Google Scholar
• Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43:227-38
   PubMed Web of Science ®Google Scholar
• Weinling E, McDougall S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol 2006;20:397-403
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469-80
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet 1991;21:165-77
   PubMed Web of Science ®Google Scholar
• Ambien-CR TM [package insert]. Bridgewater, NJ: Sanofi-Aventis, US; 2005
   Google Scholar
• Thenot JP, Hermann P, Durand A, et al. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: Imidazopyridines in Sleep Disorders. Sauvanet JP, Langer SZ, Morselli PL, editors. New York: Raven Press; 1988. p. 139-53
   Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999;48:89-97
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Perloff MD, et al. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 2002;23:361-7
   PubMed Web of Science ®Google Scholar
• Darcourt G, Pringuey D, Salliere D, Lavoisy J. The safety and tolerability of zolpidem – an update. J Psychopharmacol 1999;13:81-93
   PubMed Web of Science ®Google Scholar
• Hindmarch,I, Stanley N, Legangneux E, Emegbo S. Zolpdiem modified-release significantly reduces latency to persistent sleep 4 and 5 hours postdose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening [abstract]. Sleep 2005;28:A245-6
   Google Scholar
• Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406
   PubMed Web of Science ®Google Scholar
• Erman M, Krystal A, Zammit G, et al. Long-term efficacy of zolpidem extended-release in the treatment of sleep maintenance and sleep onset insomnia with improvements in next-day functioning [abstract]. Sleep 2007;30:A241
   Google Scholar
• Roehrs T, Soubrane C, Roth T. Zolpidem modified-release objectively and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia [abstract]. Sleep 2005;28:A244
   Google Scholar
• Blin O, Micallef J, Audebert C, Legangneux E. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol 2006;26:284-9
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Legangneux E, Stanley N, et al. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006;62:538-45
   PubMed Web of Science ®Google Scholar
• Erman M, Krystal A, Zammit G, et al. No evidence of rebound insomnia in patients with chronic insomnia treate with zolpidem extended-release 12.5 mg administered ‘as needed’ 3-7 nights/week for 6 months [abstract]. Sleep 2007;30:A241-2
   Google Scholar